Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00134134 · ClinicalTrials.gov registry record · Phase 1
Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa
A Phase 1 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT00134134 is a Phase 1 study that has completed, run by NYU Langone Health. The registered enrollment target is 5 participants.
The verdict
NCT00134134, a Phase 1 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness and safety of efalizumab in treating hydradenitis suppurativa, and to evaluate the duration of the benefit seen in people who respond to treatment with efalizumab, after the medication is stopped.
Interventions
- DRUG efalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2005-02 |
| Est. Completion | 2006-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00134134
The ClinicalTrials.gov registry entry for NCT00134134 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which efalizumab is the first listed.
NCT00134134 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00134134 about?
NCT00134134 is a clinical study titled "Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa". The purpose of this study is to determine the effectiveness and safety of efalizumab in treating hydradenitis suppurativa, and to evaluate the duration of the benefit seen in people who respond to treatment with efalizumab, after the medication is stopped.
What is the current status of trial NCT00134134?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2005-02. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00134134?
The interventions under investigation include: efalizumab (DRUG).
Who is sponsoring clinical trial NCT00134134?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.